Home › Non-Muscle Invasive Bladder Cancer › Florida › Tampa
Non-Muscle Invasive Bladder Cancer clinical trials in Tampa, FL
5 studies for Non-Muscle Invasive Bladder Cancer are looking for participants at sites in and around Tampa (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer
RecruitingPhase 2
- Moffitt Cancer Center, Tampa
A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
RecruitingPhase 1
- Moffitt Cancer Center - International Plaza, Tampa
- Moffitt Cancer Center - McKinley Campus, Tampa
- Moffitt Cancer Center, Tampa
- and 1 more
Exploration of Novel AI-enabled Blue Light Enhanced Cystoscopy
RecruitingObservational study
- Moffitt Cancer Center, Tampa
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)
RecruitingPhase 1/2
- Moffitt Cancer Center ( Site 0057), Tampa
Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2
RecruitingObservational study
- H. Lee Moffitt Cancer Center & Research Institute, Tampa
Non-Muscle Invasive Bladder Cancer trials in other cities
- Columbus, OH10 studies
- Dallas, TX10 studies
- New York City, NY10 studies
- Myrtle Beach, SC9 studies
- Edison, NJ9 studies
- Baltimore, MD8 studies
- Nashville, TN8 studies
- Syracuse, NY8 studies
- Houston, TX7 studies
- Indianapolis, IN7 studies
- Birmingham, AL7 studies
- Philadelphia, PA7 studies
Other studies in Tampa
- Non-Small Cell Lung Cancer51 studies
- Breast Cancer43 studies
- Cancer (all types)39 studies
- Colorectal Cancer34 studies
- Acute Myeloid Leukemia29 studies
- Metastatic Cancer29 studies
- Lung Cancer29 studies
- Pancreatic Cancer26 studies
- Ovarian Cancer21 studies
- Melanoma19 studies
- Myelodysplastic Syndromes19 studies
- Prostate Cancer18 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.